Krystal Biotech (KRYS) Long-Term Investments (2019 - 2026)

Krystal Biotech has disclosed Long-Term Investments across 7 years of filings, most recently posting $193.5 million for Q1 2026.

• Long-Term Investments for Q1 2026 came in at $193.5 million, up 30.32% year-over-year; the trailing twelve-month figure through Mar 2026 was $193.5 million (up 30.32% YoY), and the FY2025 annual result was $128.1 million, down 15.81% from the prior year.
• Long-Term Investments came in at $193.5 million for Q1 2026 at Krystal Biotech, up from $128.1 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $193.5 million in Q1 2026 to a low of $4.6 million in Q4 2022.
• The 5-year median for Long-Term Investments is $69.3 million (2024), against an average of $79.3 million.
• Across the five-year window, Long-Term Investments plunged 92.82% in 2022 and soared 1537.67% in 2024, its largest moves.
• Krystal Biotech's Long-Term Investments stood at $4.6 million in 2022, then soared by 1240.71% to $62.0 million in 2023, then jumped by 145.53% to $152.1 million in 2024, then decreased by 15.81% to $128.1 million in 2025, then soared by 51.08% to $193.5 million in 2026.
• The last three Long-Term Investments figures came in at $193.5 million (Q1 2026), $128.1 million (Q4 2025), and $133.1 million (Q3 2025), per Business Quant data.